1. Home
  2. EOLS vs IMOS Comparison

EOLS vs IMOS Comparison

Compare EOLS & IMOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • IMOS
  • Stock Information
  • Founded
  • EOLS 2012
  • IMOS 1997
  • Country
  • EOLS United States
  • IMOS Taiwan
  • Employees
  • EOLS N/A
  • IMOS N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • IMOS Semiconductors
  • Sector
  • EOLS Health Care
  • IMOS Technology
  • Exchange
  • EOLS Nasdaq
  • IMOS Nasdaq
  • Market Cap
  • EOLS 787.7M
  • IMOS 813.1M
  • IPO Year
  • EOLS 2018
  • IMOS N/A
  • Fundamental
  • Price
  • EOLS $11.35
  • IMOS $19.15
  • Analyst Decision
  • EOLS Strong Buy
  • IMOS
  • Analyst Count
  • EOLS 6
  • IMOS 0
  • Target Price
  • EOLS $22.60
  • IMOS N/A
  • AVG Volume (30 Days)
  • EOLS 504.4K
  • IMOS 27.3K
  • Earning Date
  • EOLS 11-06-2024
  • IMOS 11-05-2024
  • Dividend Yield
  • EOLS N/A
  • IMOS 6.10%
  • EPS Growth
  • EOLS N/A
  • IMOS 7.03
  • EPS
  • EOLS N/A
  • IMOS 0.07
  • Revenue
  • EOLS $248,326,000.00
  • IMOS $724,842,895.00
  • Revenue This Year
  • EOLS $33.43
  • IMOS $15.65
  • Revenue Next Year
  • EOLS $32.44
  • IMOS $13.49
  • P/E Ratio
  • EOLS N/A
  • IMOS $12.84
  • Revenue Growth
  • EOLS 34.42
  • IMOS 13.31
  • 52 Week Low
  • EOLS $9.65
  • IMOS $18.20
  • 52 Week High
  • EOLS $17.82
  • IMOS $32.19
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 35.09
  • IMOS 42.28
  • Support Level
  • EOLS $11.34
  • IMOS $18.20
  • Resistance Level
  • EOLS $11.83
  • IMOS $19.40
  • Average True Range (ATR)
  • EOLS 0.46
  • IMOS 0.24
  • MACD
  • EOLS -0.00
  • IMOS 0.01
  • Stochastic Oscillator
  • EOLS 14.41
  • IMOS 55.88

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. The Company derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

Share on Social Networks: